The global rare disease genetic testing market, valued at USD 1.05 billion in 2023, is projected to reach an impressive USD 3.79 billion by 2032, expanding at a strong CAGR of 15.36% during the forecast period 2024–2032. Increasing awareness, technological innovation, and strong government backing are driving widespread adoption of genetic testing in diagnosing and managing rare diseases across the globe.
Growth Drivers Accelerating Market Expansion
The rapid evolution of genomic technologies has paved the way for earlier and more precise diagnosis of rare genetic conditions. Next-generation sequencing (NGS), in particular, has revolutionized rare disease diagnostics, allowing for high-throughput testing at significantly lower costs. With millions of people worldwide affected by rare diseases—many of which are genetic in origin—early detection has become a public health priority.
Government initiatives such as the U.S. “All of Us” Research Program, India’s Genome India Initiative, and China’s 1 Million Genomes Project are expanding access to genetic screening. Meanwhile, academic institutions and private sector players are collaborating to bring innovation and affordability to rare disease diagnostics. With healthcare providers shifting toward precision medicine, genetic testing is becoming a core component of personalized treatment strategies.
Get a Free Sample Report of Rare Disease Genetic Testing Market@ https://www.snsinsider.com/sample-request/6397
Market Segmentation Analysis
By Disease Type:
Immunological disorders held the dominant market share of 10.5% in 2023. The rise in autoimmune and immune deficiency diseases has significantly increased the demand for early and accurate diagnosis, with governments and research institutions investing heavily in immunogenetics.
The endocrine & metabolism disorders segment is the fastest-growing, fueled by a surge in awareness about inherited metabolic disorders and the expansion of newborn screening programs. The increasing availability of accessible and non-invasive testing platforms has further supported the segment’s growth.
By Technology:
Next-generation sequencing (NGS) emerged as the leading technology in 2023, accounting for 33.9% of the market. The advantages of NGS—including the ability to simultaneously analyze multiple gene mutations and reduce diagnostic timelines—have made it a gold standard for rare disease diagnostics. Falling sequencing costs and improved bioinformatics platforms continue to boost adoption.
By Specialty:
Molecular genetic testing accounted for the largest share, at 38.2%, due to its unmatched precision in detecting single-gene and inherited mutations. The growing demand for comprehensive approaches like whole-exome and whole-genome sequencing has further propelled this segment forward.
By End-Use:
Research laboratories and contract research organizations (CROs) held the highest market share in 2023, with 43.6%, reflecting the significant investment in R&D and clinical trials related to rare diseases. Pharmaceutical collaborations, along with the need for complex genetic analysis for drug discovery, have made this segment a leader.
Diagnostic laboratories are the fastest-growing segment, reflecting a shift toward integrating genetic testing into routine clinical diagnostics. Increased awareness among clinicians and patients, as well as supportive regulatory frameworks, are facilitating this trend.
Regional Insights
North America remains the global leader in rare disease genetic testing, thanks to a sophisticated healthcare infrastructure, favorable reimbursement policies, and national genomics initiatives. The U.S. leads with projects like the NIH’s Undiagnosed Diseases Network and widespread adoption of sequencing technologies by firms such as Illumina, Invitae, and Natera.
Europe follows closely, bolstered by the EU’s Orphan Drug Regulation and investments in genomic integration into public healthcare systems. Countries like the UK (via Genomics England), France, and Germany are enhancing patient access to genetic screening through national programs.
Asia-Pacific is projected to grow at the fastest rate, driven by expanding healthcare spending, technological advancements, and supportive government policies. China, India, and Japan are spearheading the region’s growth through national genome sequencing programs, rare disease research funds, and expanded screening initiatives. Japan’s USD 1.3 billion investment in rare disease research stands as a testament to the region’s commitment.
Need Any Customization Research on Rare Disease Genetic Testing Market, Enquire Now@ https://www.snsinsider.com/enquiry/6397
Competitive Landscape
The market is highly fragmented, with key players offering a broad range of genetic testing panels, exome and genome sequencing services, and bioinformatics solutions. Companies are also focusing on affordability and access through digital platforms and strategic partnerships.
Major Players Include:
Quest Diagnostics Inc. – Neurome, ClariTest
Centogene N.V. – CentoGenome, CentoMetabolic
Invitae Corp. – Rare Disorders Panel, Neuromuscular Disorders Panel
3billion, Inc. – Whole Exome Sequencing, Rare Disease Panels
ARUP Laboratories – Targeted NGS Panels for Rare Diseases
Eurofins Scientific – NMD Panel, Exome NGS
Strand Life Sciences – Strand RareGen, Whole Genome Sequencing
Ambry Genetics – Rare Disease NGS Panels
PerkinElmer, Inc. – PerkinElmer Genomics, WGS
Realm IDX, Inc. – Exome Testing, Genomic Panels
Macrogen, Inc. – NGS Panels, Whole Genome Sequencing
Baylor Genetics – Exome and Gene Panels for Rare Diseases
Color Genomics, Inc. – Genetic Risk and Rare Disease Testing
Health Network Laboratories – Comprehensive Genetic Testing Panels
Recent Developments
February 2025: Strand Life Sciences launched its “StrandOmics Portal,” a digital platform streamlining rare disease diagnosis through improved access to genetic interpretation. The initiative, backed by Reliance Industries, focuses on increasing testing affordability and precision.
January 2025: The Centre for Genetic Disorders at Banaras Hindu University (BHU) in India unveiled new initiatives aimed at strengthening research and diagnostic capabilities in rare disease genetics, enhancing regional access to advanced genomic tools.
Outlook and Opportunities
The rising global focus on rare diseases—driven by both humanitarian and economic imperatives—makes the rare disease genetic testing market a high-growth domain. Demand for faster, cheaper, and more accurate diagnostics will continue to drive innovation in sequencing technologies, bioinformatics, and point-of-care solutions.
Healthcare stakeholders—including providers, payers, and policymakers—are expected to increasingly adopt value-based approaches where genetic testing plays a central role in reducing diagnostic odysseys, avoiding unnecessary treatments, and optimizing outcomes.
Moreover, the convergence of artificial intelligence with genomic data holds potential to accelerate diagnosis and uncover novel therapeutic targets. Collaborations between AI firms and diagnostic companies may usher in a new era of predictive and personalized care for patients with rare genetic conditions.
As research pipelines grow and access broadens, the market is poised for sustained expansion, offering improved quality of life for millions affected by rare diseases worldwide.
Buy a Single-User PDF of Rare Disease Genetic Testing Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6397
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
